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Abstract
Background: This work tests the hypothesis that increased levels of vascular endothelial growth factor (VEGF)
observed during bladder inflammation modulates nerve plasticity.
Methods: Chronic inflammation was induced by intravesical instillations of Bacillus Calmette-Guérin (BCG) into the
urinary bladder and the density of nerves expressing the transient receptor potential vanilloid subfamily 1 (TRPV1)
or pan-neuronal marker PGP9.5 was used to quantify alterations in peripheral nerve plasticity. Some mice were
treated with B20, a VEGF neutralizing antibody to reduce the participation of VEGF. Additional mice were treated
systemically with antibodies engineered to specifically block the binding of VEGF to NRP1 (anti-NRP1
B) and NRP2
(NRP2
B), or the binding of semaphorins to NRP1 (anti-NRP1
A) to diminish activity of axon guidance molecules such
as neuropilins (NRPs) and semaphorins (SEMAs). To confirm that VEGF is capable of inducing inflammation and
neuronal plasticity, another group of mice was instilled with recombinant VEGF165 or VEGF121 into the urinary
bladder.
Results: The major finding of this work was that chronic BCG instillation resulted in inflammation and an
overwhelming increase in both PGP9.5 and TRPV1 immunoreactivity, primarily in the sub-urothelium of the urinary
bladder. Treatment of mice with anti-VEGF neutralizing antibody (B20) abolished the effect of BCG on inflammation
and nerve density.
NRP1
A and NRP1
B antibodies, known to reduce BCG-induced inflammation, failed to block BCG-induced increase in
nerve fibers. However, the NRP2
B antibody dramatically potentiated the effects of BCG in increasing PGP9.5-,
TRPV1-, substance P (SP)-, and calcitonin gene-related peptide (CGRP)-immunoreactivity (IR). Finally, instillation of
VEGF121 or VEGF165 into the mouse bladder recapitulated the effects of BCG and resulted in a significant
inflammation and increase in nerve density.
Conclusions: For the first time, evidence is being presented supporting that chronic BCG instillation into the
mouse bladder promotes a significant increase in peripheral nerve density that was mimicked by VEGF instillation.
Effects of BCG were abolished by pre-treatment with neutralizing VEGF antibody. The present results implicate the
VEGF pathway as a key modulator of inflammation and nerve plasticity, introduces a new animal model for
investigation of VEGF-induced nerve plasticity, and suggests putative mechanisms underlying this phenomenon.
Background
It is highly likely that sensory dysfunction is involved in
various disorders of the lower urinary tract (LUT)
including neurogenic bladder, outflow obstruction, idio-
pathic detrusor instability, overactive bladder, painful
bladder syndrome, and diabetic neuropathy involving
the bladder. In addition, chronic pathological conditions
that cause tissue irritation or inflammation can alter the
properties of sensory pathways, leading to a reduction in
pain threshold and/or an amplification of painful sensa-
tion (hyperalgesia) [1]. Depending on the pathology, sev-
eral mediators and their respective receptors have been
proposed to modulate peripheral nerve plasticity in the
LUT, including but not limited to: purinergic receptors
in general [2] or P2X receptor in particular [3], transient
receptor potential vanilloid subfamily 1 (TRPV1) [1],
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vated receptors [5], and nerve growth factor and its
receptors [6].
The new hypothesis being tested in this manuscript is
that increased levels of VEGF observed during bladder
inflammation provoke nerve plasticity. This hypothesis
is based on evidence indicating that nerves and blood
vessels are associated, follow a common molecular path-
way during development, and key molecules responsible
for their development may continue to control their
plasticity in adulthood [7]. The finding that mutant
mice (neurogenin1/neurogenin2 double knockout
embryos) lacking sensory nerves also present disorga-
nized blood vessel branching [8], suggests that local sig-
nals such as VEGF supplied by nerve fibers, may
provide a cue that determines blood vessel patterning.
In contrast, administration of VEGF can support and
enhance the growth of regenerating nerve fibers, prob-
ably through a combination of angiogenic, neurotrophic,
and neuroprotective effects [9].
In this context, many proteins that were originally dis-
covered to be required for axon guidance have recently
been implicated in the development of the vascular [10]
and lymphatic systems [11]. Perhaps the most striking
observation is that angiogenic factors, when deregulated,
contribute to various neurological disorders, such as
neurodegeneration. The prototypic example of this
cross-talk between nerves and vessels is the vascular
endothelial growth factor, VEGF [12]. Although origin-
ally described as a key angiogenic factor, it is now well
established that VEGF also plays a crucial role in devel-
opment of the nervous system [12].
Among the neuronal guidance molecules, neuropilins
(NRPs) and plexins, and their ligands, semaphorins and
VEGF have been extensively studied in the central ner-
vous system. They represent large families of molecules
that can transduce signals essential for the regulation of
neuronal repulsion and attraction, cell shape, motility,
and cell-cell interactions [13-15].
Plexins are similar to the Toll-like receptors (TLRs) in
their evolutionary conservation from flies to mammals.
In particular, plexin A4 has been shown to be required
for bacteria and LPS to engage TLR and trigger the
downstream signal transduction pathway including acti-
vation of Rac1, c-Jun N-terminal kinase, NF-kB and AP-
1 [16]. In addition, plexin-A4 in macrophages is
required for optimal cytokine production, including
TNFa and IL-6, upon bacterial challenge [16].
NRPs are transmembrane glycoproteins that were
initially identified as co-receptors for plexin that mediate
the effects of class-3 semaphorins on axon guidance
[17]. NRP-1 has high affinity for Sema-3A, whilst NRP-2
homodimers have high affinity for Sema-3F [18]. The
diversity of function of these guidance molecules resides
in their capacity to also function as co-receptors for
VEGF enhancing its binding to VEGF receptors [19]. It
has become clear that in the adult organism, NRPs par-
ticipate in many processes, such as angiogenesis and
immune response [20]. NRP1 is associated with blood
vessel development, whereas NRP2 was initially identi-
fied as a semaphorin receptor, and mediator of axon
guidance [17] and lymphatic vessel development [21].
Of relevance to the present study, NRPs are highly
expressed in the human [22] and mouse bladder urothe-
lium and intramural ganglia in close association with
VEGF receptors [23]. Moreover, urothelial-related dis-
eases and BCG-induced inflammation alter NRP expres-
sion and the accessibility of VEGF to these receptors
[22,23]. In addition, NRPs also regulate neuronal plasti-
city as indicated by mutant mouse studies, showing that
peripheral nerve regeneration is delayed in neuropilin 2-
deficient mice [24]. The latter observation raises the
question of whether upregulation of VEGF and guidance
molecule expression during inflammation would also
lead to altered nerve plasticity.
Little information is available regarding SEMA con-
centrations in non-malignant bladders. Semaphorins are
a large family of signaling proteins that are both
secreted and membrane bound. A common theme in
the mechanisms of semaphorin function is that they
alter the cytoskeleton and organization of actin fila-
ments and the microtubule network [25]. Class 3 sema-
phorins (Sema3A-G) are the only secreted forms in
vertebrates. Among the class 3 semaphorins, Sema3A
has been most intensively studied in relation to axon
guidance [26] and intrathecally administered Sema3A
protein attenuates neuropathic pain behavior in rats
with chronic constriction injury of the sciatic nerve [27].
Sema3A shows repulsive activity toward a variety of
neuronal types [28]. Sema3A and its receptors (NRP1,
NRP2, plexin A1, plexin A2, and plexin A3) were found
to be significantly increased during M-CSF-mediated
differentiation of monocytes into M2 macrophages of
the inflammatory phenotype [29].
Relative to cross-talk among signaling molecules, it is
interesting that VEGF and semaphorins have opposite
effects on the filopodia of both endothelial cells (ECs)
and axons expressing neuropilins. Sema3F, the sema-
phorin ligand of NRP2, is known to repel nerves [30]
and endothelial cells [31], whereas VEGF165 attracts the
filopodia, which drives the ECs or axons to move in the
direction of the VEGF gradient [30].
For these studies, BCG was chosen to induce cystitis
because it is known to: a) provoke a significant increase
in VEGF expression in the urinary bladder [32], b)
cause profound inflammation that is dependent on the
VEGF pathway [33], c) up-regulate the urothelial expres-
sion of VEGF receptors and NRPs [23], and d)i n d u c e
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necessary for nerve regeneration [34].
T h ei n n o v a t i v er e s u l t so ft h is research provide evi-
dence that chronic inflammation induces alterations of
bladder peripheral nerve density that express: a) the
transient receptor potential vanilloid subfamily 1
(TRPV1) [35], b) protein gene product (PGP9.5)[36], c)
substance P, and d) calcitonin gene-related peptide
(CGRP). Results obtained with potent and specifically
engineered neutralizing antibodies against VEGF, NRP1,
and NRP2 further suggest a putative mechanism under-
lying inflammation-induced increase in peripheral nerve
density. Furthermore, instillation of VEGF into the blad-
der recapitulated the effects of BCG on inflammation
and nerve plasticity.
Results
Chronic instillation of BCG, VEGF165, and VEGF121 result in
bladder inflammation
As BCG [33] and VEGF121 [22] once instilled into the
mouse bladder are absorbed across apparently intact
urothelium and systemically distributed [22], we sought
to compare the degree of inflammatory cell infiltrate in
response to these stimuli. Because VEGF165 contains
amino acid residues that bind to heparin and heparan
sulfate proteoglycans, it is pa r t l yd i f f u s i b l ea n dp a r t l y
bound to the pericellular matrix [12] which may explain
its poor diffusion into deeper bladder layers. Therefore,
we decided to also test the VEGF121 isoform that is
freely diffusible [12], since it lacks the basic amino acid
residues responsible for heparin binding and, therefore,
does not, or only minimally, binds to the extracellular
matrix (ECM). Figure 1 illustrates inflammation in
response to chronic instillations of BCG, VEGF165 and
VEGF121. This illustration shows a predominant cellular
infiltrate in response to chronic BCG instillation,
whereas VEGF165 and VEGF121 h a v eam o r ep r o f o u n d
impact in the bladder vascular system leading to dilation
of both arteries and veins. Higher magnification inserts
are amplification of dashed square areas of the respec-
tive figures and illustrate inflammatory cells and perivas-
cular infiltrates (Figure 1).
Next, double immunofluorescence was used to further
clarify whether the inflammatory infiltrate in response
of BCG and VEGF was composed of MPO+ and F4/80+
cells (Figure 2). Quantitative analysis of MPO+ and F4/
80+ cells indicate that chronic BCG instillation induces
both neutrophils and macrophages infiltrations (Figure
3). In the sub-urothelium, BCG induced predominantly
neutrophils (Figure 3A and 3B) that were almost double
the number of macrophage (Figure 3C and 3D). These
results are summarized on Table 1.
As bladder instillation with BCG is known to provoke
a significant increase in VEGF levels [32,33]
concomitant to up-regulation of VEGF receptors and
co-receptors (NRPs) [23], we tested whether BCG-
induced inflammation was dependent on VEGF. To
remove the influence of VEGF, an additional group of
mice received systemic treatment with neutralizing
VEGF antibody twice a week, concomitant to four
weekly instillations of BCG. The results presented in
Figure 3 indicate that neutralization of VEGF by B20
resulted in a blunted inflammatory response character-
ized by a reduction of both neutrophils and macro-
phages towards baseline levels. As these results suggest
that VEGF participates in bladder inflammation, addi-
tional groups of mice received instillations of VEGF165
and VEGF121. Interestingly, both forms of VEGF
induced a predominant infiltration of macrophages in
the sub-urothelial layer (Figure 4C and table 1) and, to a
lesser extent when compared to BCG (Figure 3A and
Table 1), some neutrophil infiltration (Figure 4A and
Table 1).
BCG-induced inflammation results in bladder nerve
plasticity
In order to determine whether chronic bladder inflam-
mation results in alteration of nerve density, we first
determined the distribution of sensory nerves expressing
the nociceptive transducer vanilloid type 1 transient
receptor potential receptor (TRPV1) in the urinary blad-
der isolated from control mice. The results illustrated in
Figure 5A confirmed the reported distribution of
TRPV1 immunoreactivity (IR) in the rat bladder [1] and
extend the results to nerves crossing the urothelial layer
(Figure 5C) or surrounding urothelial cells (Figure 5D).
TRPV1 antibody specificity was verified by comparing
the labeling of bladders isolated from C57BL/6 (Figure
5 A )u s e da sap o s i t i v ec o n t r o la n dT R P V 1
-/- mice [37]
used as a negative control (Figure 5B) to bladders from
WT mice (TRPV1
+/+; Figures 5C-D). No immunostain-
ing was observed in bladders isolated from TRPV1
-/-
mice (Figure 5B), indicating that this antibody specifi-
cally identifies TRPV1-IR in the urothelium, sub-urothe-
lium, and detrusor nerve fibers (Figures 6A-B). Figures
6A and 6B are low magnification micrographs in order
to illustrate the distribution of TRPV1-positive fibers in
several layers of the urinary bladder isolated from con-
trol (PBS) and inflamed bladders (BCG), respectively.
Regardless of magnification, Figures 6A-B illustrate that
inflammation induced a higher degree of TRPV1-IR in
the sub-urothelium of bladders isolated from BCG-trea-
ted mice that was confirmed by image analysis (Figure
7). Next, we compared TRPV1-IR with other nerve mar-
kers. For this purpose, tissues isolated from the same
groups were also stained with antibodies identifying
CGRP (Figures 6C-D), PGP9.5 (Figures 5E-F), and SP
(Figures 6G-H). It was noted that PGP9.5 and CGRP
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urothelial layer. A reasonable explanation for this arti-
fact is that the methods recommended for permeabiliza-
tion of the tissues caused such labeling. These findings
precluded the use of the urothelium for quantification
purposes, and image analysis was performed in two
layers: the detrusor smooth muscle and the sub-urothe-
l i u mt h a te x t e n d e df r o mt h eb a s a ll a y e ro ft h eu r o t h e -
lium to detrusor. Results obtained with image analysis
indicate that BCG induced a significant increase in the
pan-neuronal marker PGP9.5-IR in the sub-urothelium
and detrusor smooth muscle (Figure 8) and an increase
in sensory nerve marker TRPV1-IR, specifically in the
sub-urothelium (Figure 8). BCG also induced a signifi-
cant increase in CGRP- and SP-IR (Figure 7).
VEGF mediates BCG-induced alterations in bladder nerve
plasticity
It was reported that VEGF is expressed in nerves at rela-
tively higher amounts than in the surrounding mesench-
y m a lt i s s u e[ 8 ] ,a n dan e wa p p r e c i a t i o no ft h er o l eo f
VEGF in neuronal development emerged [12,38] that
made us review a possible link between BCG-induced
inflammation and bladder nerve plasticity with the activ-
ity of VEGF. As neutralization of VEGF by B20 resulted
in a blunted inflammatory response to BCG (Figure 3),
next we investigated whether BCG-induced alteration in
nerve plasticity was also modulated by VEGF. Tissues
obtained from mice that received PBS, BCG, or BCG
and B20 were submitted to image analysis to quantify
PGP9.5- and TRPV1-IR in the sub-urothelium and
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Figure 1 Mouse bladder inflammation. Representative photomicrographs from the urinary bladders isolated from mice chronically treated
with 4 weekly instillations of PBS (A), BCG (B), VEGF165 (C), and VEGF121 (D). Black box inserts on B, C, and D correspond to a 200%
magnification of the original dashed box area of the respective figures and illustrate inflammatory cells. White transversal bars indicate the
urothelium, yellow bars indicate the sub-urothelium, and green bars indicate the detrusor smooth muscle. Green arrow indicates perivascular
infiltrate of inflammatory cells (D). See Figures 2 and 3 for quantification of inflammatory cells by image analysis.
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Figure 2 Representative photomicrographs of double immunofluorescence (MPO and F4/80) of the urinary bladder mucosa isolated
from mice that received 4 weekly instillations of BCG (A and D), VEGF165 (B and E), and VEGF121 (C and F). Qualitatively all stimuli
induced the migration of both F4/80+ macrophages and MPO+ neutrophils. Quantification of the results is being present in Figures 3 and 4 and
summarized on Table 1. D, E, and F correspond to magnification of the original dashed box area of the respective figures A, B, and C.
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Figure 3 Chronic BCG instillation induces a predominant migration of myeloperoxidase-positive neutrophils and, to a lesser extent,
F4/80-positive macrophages that are blunted by co-treatment with VEGF neutralizing antibody (B20). Quantification of myeloperoxidase-
IR (A-B) and F4/80-IR (C-D) in the sub urothelium and detrusor muscle of bladders isolated from: control (mice receiving i.p. PBS [twice a week]
concomitant to 4 weekly instillations of PBS), BCG-treated (mice receiving i.p. PBS [twice a week] concomitant to 4 weekly instillations of BCG),
and B20-treated (mice receiving i.p. B20 [5 mg/kg; twice a week] concomitant to 4 weekly instillations of BCG). N = 8 per group. Statistical
significance was set for p values < 0.05.
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ures 8 indicate that neutralization of VEGF by B20 com-
pletely blocked the capacity of BCG to increase PGP9.5
(Figures 8A-B) and TRPV1-IR (Figures 8C-D) suggesting
that the observed increase in nerve plasticity was
mediated by VEGF acting either directly or indirectly on
the nerves. Control experiments included treatment of
mice with Avastin that recognizes and neutralizes
human VEGF but is inactive against mouse VEGF.
Avastin did not alter the enhanced innervation of the
urinary bladder following instillation of BCG in mice
(data not shown).
Blocking NRP antibodies
To further explore the mechanism involved in VEGF
mediated inflammation and nerve plasticity, we used
Table 1 Comparisons between BCG- and VEGF-induced inflammatory cell migration (MPO and F4/80), vascular
response (CD31), and nerve plasticity (PGP9.5 and TRPV1) in the sub-urothelial layer of the mouse bladder.
%PBS BCG 1 WK VEGF165 1 WK VEGF165 4 WKS VEGF165 6 WKS VEGF121 1 WK
MPO 1, 682 ± 442 107 ± 33 441 ± 91 363 ± 77 222 ± 44
F4/80 190 ± 31 252 ± 48 318 ± 40 398 ± 102 414 ± 58
CD31 163 ± 7 251 ± 22 144 ± 14 167 ± 25 220 ± 15
PGP9.5 414 ± 48 533 ± 74 257 ± 44 385 ± 67 151 ± 40
TRPV1 223 ± 14 205 ± 11 183 ± 20 146 ± 20 134 ± 17
Individual values illustrated on Figures 3, 4, 8, 9, 10, 11, and 13A were expressed as % of the respective PBS group and the average ± standard error of the mean
are summarized.
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Figure 4 VEGF induces bladder inflammation. Quantification of myeloperoxidase-IR (A-B) and F4/80-IR (C-D) in the sub urothelium and
detrusor muscle of bladders isolated from: 4 weekly instillations with PBS, single instillation with VEGF165, 4 weekly instillations with VEGF165,6
weekly instillations with VEGF165, a single instillation with VEGF121, and 4 weekly instillations of VEGF121. Mice were euthanized one week after
the last instillation and the urinary bladders removed for IF. N = 8 per group. Statistical significance was set for p values < 0.05.
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coupling is significantly more effective than other
approaches in decreasing VEGF-VEGFR2 signaling
[39,40]. Based on the capacity of NRP antibodies to sig-
nificantly reduce lymphatic vessel proliferation and neu-
trophil migration during chronic bladder inflammation
induced by BCG [33], we tested whether the blockade of
NRP1 or NRP2 with engineered antibodies would also
alter the effect of BCG on bladder nerve density. Figures
9A-D indicate that concomitant treatment with NRP1
A
or NRP1
B did not change the capacity of BCG to induce
an increase of TRPV1-IR or PGP9.5-IR. These results
suggest that NRP1 may not be involved in BCG-induced
bladder neuronal plasticity. Surprisingly, blockade of
TRPV1
DAPI
TRPV1
DAPI
TRPV1
DAPI
TRPV1
DAPI
TRPV1 KO
 
50 +m 50 +m
10 +m
10 +m
A B
C D
Figure 5 TRPV1-IR in the mouse urinary bladder. Representative photomicrograph illustrating distribution of TRPV1-IR in the urinary bladder
isolated from C57BL/6 mice receiving chronic PBS instillation (A) shows TRPV1-IR extending from the base (cyan arrow) of the urothelium (white
transversal bar) towards the sub-urothelium (yellow transversal bar). B) No immunostaining was observed in bladders isolated from TRPV1
-/- mice
indicating that this antibody specifically identifies TRPV1-IR nerve fibers. C indicates some TRPV1-positive nerves crossing the urothelial layer
(white arrows) and D illustrates TRPV1-positive nerves surrounding urothelial cells. White waved line on D highlights the bladder lumen.
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strong potentiation of BCG effects on sub-urothelial
PGP9.5-IR (Figure 9A). Regarding TRPV1-IR, NRP2
B
did not further enhance the substantial increase in sen-
sory nerves induced by BCG in the sub-urothelium (Fig-
ure 9C). However, the combination of BCG and NRP2
B
treatments resulted in a significant increase of TRPV1-
IR in the detrusor muscle (Figure 9D).
Substance P and CGRP-IR positive nerves are also
increased by the combination of BCG and NRP2
B
To further explore the effects of combined therapy of
NRP2
B and BCG, we tested whether increased nerve plas-
ticity was specific for TRPV1-IR or a general effect on
sensory nerves expressing other markers such as SP and
CGRP. Combined treatment of NRP2
B and BCG induced
a significant increase of CGRP-IR in the sub-urothelium
(Figure 10A) and detrusor muscle (Figure 10B) and sub-
stance P-IR in the sub-urothelium (Figure 10C).
VEGF instillation induces bladder nerve plasticity
To provide direct evidence that VEGF induces bladder
neuronal plasticity, VEGF165 and VEGF121 were instilled
into the mouse bladder either acutely (1 WK = single
instillation of VEGF and mice were euthanized one
week after) or chronically (4 WKs = four weekly instilla-
tions of VEGF and tissues removed 1 week after the last
instillation). In order to determine if the bladder
responses to VEGF165 have reached a plateau, an addi-
tional group received six weekly instillations of VEGF165
and was euthanized 1 week after the last instillation.
One week after a single instillation of VEGF165 into the
mouse bladder, a substantial increase in the number of
PGP9.5-IR and TRPV1-IR fibers was observed, and this
increase was at least double the basal number of nerves
in the sub-urothelium and detrusor smooth muscle (Fig-
ure 11). After the 4
th weekly treatment with VEGF165,a
tempering of the response was observed. In addition to
VEGF165,V E G F 121 significantly increases PGP9.5-IR in
nerves running into the detrusor smooth muscle (Figure
11B) and TRPV1 fibers in the sub-urothelium (Figure
11C) and detrusor smooth muscle (Figure 11D). Table 1
summarizes these results.
Differences between bladder responses to BCG and VEGF
The effects of chronic instillation of BCG, VEGF121,o r
VEGF165 into the mouse bladder on microvessel density
and cell proliferation were conducted by determining
the area of CD31-positive blood vessels an the expres-
sion of KI67. Figure 12 contains representative photomi-
crographs of CD31 positive microvessels along with the
expression of KI67. In tissues obtained from BCG-trea-
ted mice, KI67 expression was predominantly observed
on urothelial cells (waved blue lines on Figure 12) and
TRPV1
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Figure 6 Mouse bladder nerves. Representative photomicrographs illustrating distribution of IR for: TRPV1 (A-B), CGRP (C-D), PGP9.5 (E-F), and
SP (G-H) in urinary bladders isolated from C57BL6 mice that received chronic PBS instillation (left panels) or chronic BCG instillation (right
panels). White transversal bars indicate the urothelium, yellow bars indicate the sub-urothelium, and green bars indicate the detrusor smooth
muscle. Yellow arrows indicate non-specific labeling of urothelial cells with PGP9.5 (F) and CGRP (C). See Figure 6 for quantification of IR by
image analysis.
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Page 8 of 20to a lesser extend in CD31+ blood vessels (Figure 12A)
whereas in tissues isolated from VEGF121-( F i g u r e1 2 B )
and VEGF165-treated mice (Figure 12C), in addition to
urothelial cells, a strong expression of KI67 occurred on
CD31+ blood vessels. Figure 13A compare the CD31+
microvessel density on tissues stimulated with BCG or
VEGF. Figure 13B presents the quantification of KI67
taking the CD31+ cells as region of interest and indi-
cates that in contrast to BCG, chronic VEGF instillation
into the mouse bladder induced angiogenesis.
DETRUSOR
SUB-UROTHELIUM 
A
B
p=0.009
p=0.0001
p=0.0001
p=0.0001
p=0.0001
NS
p=0.0001
p=0.0001
Figure 7 Chronic BCG instillation increases IR for the pan neuronal marker, PGP9.5, and sensory nerve markers, TRPV1, SP, and CGRP.
Quantification of PGP9.5- TRVP1-, SP-, and CGRP-IR in the sub urothelium (A) and detrusor muscle (B) of bladders isolated from: control (mice
receiving i.p. PBS [twice a week] concomitant to 4 weekly instillations of PBS) and BCG-inflamed mice (mice receiving i.p. PBS [twice a week]
concomitant to 4 weekly instillations of BCG). N = 8 per group. Statistical significance was set for p values < 0.05. NS = non significant.
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This manuscript presents a body of evidence implicating
VEGF signaling in the enhanced innervation of the urin-
ary bladders following instillation of BCG in mice. Qua-
litatively these results add to a list of evidence
implicating the VEGF pathway in the bladder responses
to BCG. A quantitative analysis of inflammatory infil-
trate and vascular plasticity indicates possible alternative
pathways activated by BCG and VEGF.
The nervous and vascular systems share several anato-
mical parallels. Both systems utilize a complex branch-
ing network of neuronal cells or blood vessels reaching
all regions of the body. The anatomical similarity of the
nervous and vascular systems suggests that axons might
guide blood vessels and vice versa [30]. Indeed, signal
molecules produced by peripheral neuronal cells, such
as VEGF [8], guide blood vessels [12], and signals from
vessels, such as the neurotrophins NGF and NT-3, are
required for, and orchestrate extension of neurons adja-
cent to vessels [41]. In this manner, the neuronal and
vascular systems are well organized and coordinated in
normal adult tissues. However, in chronic inflammatory
states particularly in the LUT, little is known about how
the nerve-vessel relationship functions and whether it
could underlie the chronic pain syndrome observed in
certain patients.
Interest in guidance molecules, and particularly VEGF,
modulating both vascular and neuronal pathology is
emerging. VEGF levels are associated with alterations in
the bladder vascular system. VEGF is increased in blad-
ders of patients with painful bladder syndrome, and it is
associated with glomerulations on hydrodistension [42].
However, increased bladder VEGF is not observed in
patients who failed to show petechial bleeding or in
controls [42]. In addition, VEGFR-1 and NRP2 expres-
sions are reduced in bladder biopsies from patients with
cystitis [22].
We reasoned that pro-inflammatory stimuli known to
increase VEGF, and in particular NRP expression, might
also modulate inflammation-induced nerve plasticity.
The contribution of chronic inflammation to peripheral
nerve plasticity was investigated in a murine model
using BCG instillations that it is known to increase sig-
naling molecules, such as IL-17 [34] and VEGF [23],
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Figure 8 VEGF mediates chronic BCG-induced bladder nerve plasticity. Quantification of PGP9.5-IR (A-B) and TRPV1-IR (C-D) in the urinary
bladder isolated from: control (mice receiving i.p. PBS [twice a week] concomitant to 4 weekly instillations of PBS), BCG-treated (mice receiving i.
p. PBS [twice a week] concomitant to 4 weekly instillations of BCG), and B20-treated (mice receiving B20 [twice a week] concomitant to 4 weekly
instillations of BCG). N = 8 per group. Statistical significance was set for p values < 0.05.
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Page 10 of 20that are necessary for inducing neuronal plasticity. Our
results confirmed our hypothesis that intravesical instil-
lation of BCG increased the density of PGP9.5-, SP-,
TRPV1-, and CGRP-IR within the bladder wall. For
some parameters, the numbers of sensory nerves
identified closely parallels numbers of PGP9.5 immunor-
eactive nerves, which (accepting the limitations of sensi-
tivity of staining techniques) could indicate that most
PGP9.5 fibers observed were peptidergic sensory nerves.
However, further studies on sympathetic nerve staining
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Figure 9 Effect of NRP1 and NRP2 blocking antibodies on BCG-induced bladder nerve plasticity. Quantification of PGP9.5-IR (A-B)a n d
TRPV1-IR (C-D) in the urinary bladder isolated from: control (mice receiving i.p. PBS [twice a week] concomitantly with 4 weekly instillations of
PBS), BCG-treated (mice receiving i.p. PBS [twice a week] concomitant to 4 weekly instillations of BCG), NRP1
A-BCG treated (mice receiving NRP1
A
[twice a week] concomitant to 4 weekly instillations of BCG), NRP1
B-BCG treated (mice receiving NRP1
B [twice a week] concomitant to 4 weekly
instillations of BCG), NRP2-BCG treated (mice receiving NRP2
B [twice a week] concomitant to 4 weekly instillations of BCG), and NRP2-PBS treated
(mice receiving NRP2
B [twice a week] concomitant to 4 weekly instillations of PBS). N = 8 per group. Statistical significance was set for p values
< 0.05.
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determine the whole extend of BCG- and VEGF-
induced neuronal plasticity.
A limitation of our experimental conditions is that
concentrations of neutralizing antibodies and the pro-
inflammatory stimuli were probably different among the
different layers of the urinary bladder. The antibodies
were systemically administered, whereas pro-inflamma-
tory stimuli were instilled into the bladder. Therefore,
we analyzed the effects on both the sub-urothelium and
detrusor muscle, and the results obtained seem to reflect
differences in tissues that are in closer proximity to the
stimulus. Interestingly, BCG induced an increase of
TRPV1-IR in the sub-urothelium but not in the detrusor
smooth muscle, whereas PGP9.5-IR was found increased
in both layers. As BCG favors an increase of inflamma-
tory cells primarily in the sub-urothelial layer when
compared to the detrusor muscle, these results suggest
TRPV1-IR, but not PGP9.5-IR, is associated with the
degree of inflammatory infiltrate. In this context, in the
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Figure 10 Effect of NRP2 blocking antibodies on BCG-induced CGRP- and SP-IR. Quantification of CGRP-IR (A-B)a n dS P - I R( C-D)i nt h e
urinary bladder isolated from: control (mice receiving i.p. PBS [twice a week] concomitant to 4 weekly instillations of PBS), BCG-treated (mice
receiving i.p. PBS [twice a week] concomitantly with 4 weekly instillations of BCG), and NRP2-BCG treated (mice receiving NRP2
B [twice a week]
concomitant to 4 weekly instillations of BCG). N = 8 per group. Statistical significance was set for p values < 0.05.
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Figure 11 VEGF165 and VEGF121 recapitulate BCG-induced bladder nerve plasticity. Quantification of PGP9.5-IR (A-B) and TRPV1-IR (C-D)i n
the urinary bladder isolated 1 week after: 4 weekly instillations with PBS, single instillation with VEGF165, 4 weekly instillations with VEGF165,6
weekly instillations with VEGF165, a single instillation with VEGF121, and 4 weekly instillations of VEGF121. N = 8 per group. Statistical significance
was set for p values < 0.05.
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Figure 12 Representative photomicrographs of double immunofluorescence (CD31 and KI67) of the urinary bladder mucosa isolated
from mice instilled chronically (4 weekly instillations) of: BCG, VEGF165, and VEGF121. The area of CD31+ blood vessels was used to
calculated microvessel density (Figure 13A) and the co-localization between CD31+ endothelial cells and KI67 expression was used to calculate
the degree of angiogenesis (Figure 13 B).
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Page 13 of 20absence of inflammatory cell infiltrate, such as in IL-17
knockout mice, a significant decrease in mechanical
pain hypersensitivity was observed [43]. In contrast,
when neutrophil infiltration was increased by adminis-
tration of IL-17, a concomitant increase in neuropathic
pain was observed [43]. Furthermore, depletion of circu-
lating neutrophils at the time of nerve injury signifi-
cantly attenuated the induction of hyperalgesia [44].
Besides neutrophils and macrophages that were quan-
tified in the present study, other inflammatory cells
should be considered to have an action in neural plasti-
city. In particular, NRPs are recognized as a new marker
for regulatory T (Treg) cells [45,46] and are expressed
in antigen presenting cells and effector cells [47,48]. In
addition to NRPs, SEMAs seem to participate in inflam-
mation as it has been suggested that macrophages and
fibroblasts secrete SEMAs that may be responsible for
reduced sympathetic innervation [49]. Therefore, it is
fair to propose that one possible mechanism by which
chronic BCG instillation induces bladder neuronal plas-
ticity is by attracting inflammatory cells that will contri-
bute to increased tissue levels of VEGF or SEMA.
At this time, there is not definitive evidence correlat-
ing the type of inflammatory cell involved in the regula-
tion of bladder sensory nerve plasticity. However, given
the known trophic effects of VEGF on neurite growth
[34,50] prolonged survival of neurons [51,52], and re-
enervation following local nerve damage [53,54], it is
fair to propose that inflammatory cells producing VEGF
may be involved in the observed neural plasticity. This
new appreciation of VEGF signaling in bladder inflam-
mation is supported by emerging evidence that levels of
various VEGF subtypes are, in general, increased at the
site of inflammation, and that infiltrating lymphocytes
and other inflammatory cells represent an additional
source of VEGF [55].
The present work introduces intriguing results regard-
ing NRPs. As NRP1 has a domain structure strikingly
similar to that of NRP2 [18], we first tried to disrupt
binding of VEGF and SEMA to NRP1 using blocking
antibodies that were engineered to block either the a1-
a2 domain or b1-b2 domains of NRP1. Both antibodies,
although proven to reduce BCG-induced inflammation,
angiogenesis, and vascular remodeling [56], failed to
alter the effects of BCG on nerve density. This suggests
that either the antibodies are specific for impairing
inflammation-induced angiogenesis or that NRP1 may
not participate in mechanisms underlying neuronal plas-
ticity in the urinary bladder. An alternative explanation
is based on findings that spatial gradients of Sema3A
and VEGF may promote differential NRP1 binding [50].
Indeed, vessels expressing high levels of Sema3A favor
NRP1-PlexinA1 signaling, producing chemorepulsive
cues limiting sympathetic neurite outgrowth and vascu-
lar enervation, while low Sema3A expressing vessels
favor NRP1-VEGFR2 signaling that provides chemoat-
tractive cues for sympathetic neurite outgrowth and vas-
cular enervation [50].
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Figure 13 Effects of instillation of BCG, VEGF165, and VEGF121 into the urinary bladder resulted in alterations of vascular plasticity. (A)
Microvessel density (MVD) was determined by computing the area occupied by CD31+ blood vessels that was expressed as percent of the
cross-sectional area. (B) Angiogenesis was defined by the proliferation of CD31+ blood vessels. For this purpose, the expression of a marker of
proliferation (KI67) was calculated taking CD31+ blood vessels as region of interest (ROI).
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B
administration deserves further investigation and studies
are underway in our laboratory to define the mechanism/
s involved in bladder responses to this antibody. It is also
interesting that NRP2
B alone did not induce alteration of
nerve density. However, when given concomitantly with
BCG, NRP2
B induced an overwhelming increase in blad-
der nerve fibers. One possible explanation is that NRP2
B
might potentiate nerve plasticity by activating angiogen-
esis or increasing the migration of inflammatory cells
such as neutrophils and macrophages. Our preliminary
results indicate that NRP2
B alone does not alter bladder
blood vessel density or the number of inflammatory cells
(data not shown). However, NRP2
B does increase both
F4/80+ macrophages and MPO+ neutrophils in response
to BCG (data not shown).
It seems that in addition to activate the VEGF signal-
ing pathway, BCG may have induced an increase in
SEMAs. This would explain the finding that NRP2
B
further increased the number of nerves when adminis-
tered concomitant to BCG. As SEMAs are known for
strong chemorepulsion, these results suggest that block-
ade of NRP2 reduces SEMA participation and the con-
sequent repulsion of neurons. Although NRP2
B antibody
was originally developed to target the coagulation V/VII
factor (b1-b2) domains of NRP2 which are required for
VEGF-C binding to NRPs [21], and the b1-b2 domains
do not directly engage SEMA, this antibody could
decrease SEMA binding by preventing NRP dimerization
that is necessary for accommodating SEMA domains
that pack tightly together at this interface [57].
It is possible that other secreted semaphorins binding
to NRP2 alone are responsible for the chemorepulsion
and the consequent effect of NRP2
B antibody on neural
plasticity. NRP2 is known to be required for mediating
repulsive actions of Sema3B, 3C, and 3F, whereas NRP1
is known to be required for Sema3A function. In fact,
Sema3B and Sema3F seem to require only NRP2, not
NRP1, to elicit their effects, whereas Sema3C may
require both NRP1 and NRP2 [58]. Another piece of
evidence indicating that NRP2 may play a role in altered
nerve plasticity is the finding that peripheral nerve
regeneration is delayed in NRP2-deficient mice [24],
indicating that this guidance molecule facilitates periph-
eral-nerve axonal regeneration.
W ea l s of o u n de v i d e n c et h a tt a r g e t - d e r i v e dV E G F 165
or VEGF121 plays a previously unrecognized role in pro-
moting growth of bladder nerves and inflammation. A
role for VEGF in inflammation has been postulated.
However, instillation of VEGF into the mouse bladder
represents direct evidence that VEGF induces inflamma-
tion and that this new animal model can be used to
investigate the effects of elevated levels of VEGF on
bladder neuronal and vascular plasticity.
A fundamental question raised by the present findings
is whether the increased innervation occurred as a con-
sequence of angiogenesis or inflammation. It is known
that innervation typically accompanies blood vessels [10]
which made it important to determine whether the
observed effects on nerves are direct, or mediated
through effects on angiogenesis. This was a difficult
topic to address facing the evidence indicating an over-
lap between inflammation and angiogenesis. We found
that increased microvessel density (MVD) was part of
the bladder responses to chronic instillations of BCG,
VEGF165, and VEGF121. However, BCG did not induce a
significant endothelial cell proliferations as indicated by
KI67 and therefore, the increased MVD observed in
response to BCG was probably related to the intense
vasodilation known to be part of the inflammatory
response. In contrast, proliferating endothelial cells were
only observed in VEGF-treated tissues and, therefore, it
seems that angiogenesis underlies the bladder responses
to VEGF, as indicated by an increased KI67 expression
on CD31+ endothelial cells [59].
Although an increase in nerve density, particularly
those expressing TRPV1-IR, has been proposed to
underline pain sensation and neurogenic detrusor over-
activity based on findings that desensitization of affer-
ents with capsaicin and resiniferatoxin decrease pain
and detrusor instability [60], the present work did not
explore whether the increased nerve density corre-
sponded to an increased function of the sensory system.
The primary goal of the present work was to explore
putative mechanisms involved in inflammation-induced
neural plasticity before conducting a detailed study on
nerve function. Our results were focused on the target
organ, and future studies should include the conse-
quences of VEGF instillation on more central neurons
such as those of the dorsal root ganglia. In this context,
it should be recognized that while plasticity of the cen-
tral nervous system (in response to stimuli) and regen-
eration (in response to injury) are mainly based on
adaptive changes in neural circuits and synaptic reorga-
nization, plasticity of the peripheral nervous system is
predominantly based on axonal re-growth and neuron
addition [61].
Conclusions
VEGF is not only involved in angiogenesis, but also in
an inflammatory reaction and neuronal plasticity.
Chronic BCG administration into the mouse urinary
bladder resulted in pronounced inflammation accompa-
nied by increased density of PGP9.5, TRPV1, SP, and
CGRP nerves. BCG effects on inflammatory cells and
nerves were nullified by neutralizing VEGF antibody and
qualitatively reproduced by intravesical administration of
VEGF165 or VEGF121. However, VEGF-induced neural
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BCG-induced neural plasticity seems to be a conse-
quence of inflammation. Concomitant administration of
the VEGF-inducer, BCG, along with neutralizing anti-
NRP2 antibodies resulted in a surprising potentiation of
neuronal plasticity, whereas NRP1 antibodies did not.
The present work suggests the novel concept that both
inflammation and angiogenesis can lead to increased
bladder nerve plasticity.
Methods
Experimental Bladder Inflammation
All animal experimentation conformed to the APS’s
Guiding Principles in the Care and Use of Animals and
was approved by the OUHSC Animal Care & Use Com-
mittee (protocol #08-105). Urinary bladders isolated
from TRPV1
-/- (B6.129S4- Trpv1
tm1Jul/J; Jackson Labora-
tory) and age-matched control mice (TRPV1
+/+;W T )
were generously provided by Dr. Avelino (Faculty of
Medicine of Porto) and used for confirmation of TRPV1
antibody specificity. For all other studies, ten- to 12-
week old C57BL/6 female mice (Jackson Laboratory, Bar
Harbor, ME) were used. Female mice (n = 8 per group)
were anesthetized with ketamine HCl (40 mg/kg i.m.)
and xylazine (2.5 mg/kg i.m.), transurethrally catheter-
ized with a polypropylene catheter (24 gauge; ¾ in.;
Angiocath, Becton-Dickinson, Sandy, UT), and test com-
pounds were instilled at a slow rate to avoid trauma and
vesicoureteral reflux, 150 μl of one of the following sub-
stances were instilled: pyrogen-free saline (PBS; con-
trols), BCG (TheraCys-Aventis-Pasteur; total dose of
1.35 mg [33], mouse recombinant VEGF165 (15 nM), or
VEGF121 (15 nM). To ensure consistent contact of sub-
stances with the bladder and to avoid reflux or leakage,
the catheter was occluded and left in place for 30 min-
utes. Groups of mice were euthanized 24 hours post
instillation, and the urinary bladders were removed for
histology (H&E staining) and immunofluorescence stu-
dies. The concentrations of BCG, VEGF165,a n d
VEGF121 used in this study were selected because they
induce bladder inflammation when instilled into the
mouse bladder.
Systemic administration of neutralizing antibodies
The following blocking antibodies were administered
systemically to C57BL/6 female mice (n = 8 per group):
B20, anti-NRP1
A, anti-NRP1
B,a n da n t i - N R P 2
B.S y n -
thetic phage antibody libraries were used by Genentech,
incorporation to produce the synthetic blocking antibo-
d i e s :B 2 0 ,N R P 1 A ,N R P 1 B ,a n dN R P 2 B .T h el i b r a r i e s
were generated using a single human framework with a
template containing human consensus complementarity-
determining regions (CDRs) [62] and the antibodies that
cross-react with both human and murine NRP were
generated. B20 was isolated from synthetic antibody
phage libraries [62,63], and this neutralizing antibody
binds and blocks both human and murine VEGF [63].
Anti-NRP1
A was developed to neutralize the a1-a2
domain of NRP1 responsible for binding semaphoring
[64], and anti-NRP1
B neutralizes the b1-b2 domain
responsible for binding of VEGF [64]. Anti-NRP2
B was
developed to specifically target the coagulation V/VII
factor (b1-b2) domains of NRP2 responsible for the
binding of VEGF165 and VEGF-C and, thereby decreas-
ing lymphangiogenesis [21]. Mice were randomly
assigned to one of the following groups that received
intraperitoneal injections of 150 μl of: PBS, B20 (5 mg/
kg), control antibody (Avastin, bevacizumab, 5 mg/kg
[64]), anti-NRP1
A [10 mg/kg [64], anti-NRP1
B [10 mg/
kg [64], anti-NRP2
B (40 mg/kg). Mice were treated on
day 0, and then twice a week for 5 weeks. Mice conco-
mitantly received weekly intravesical instillations of 150
μl of PBS or BCG (TheraCys; total dose 1.35 mg,
Sanofi-Pasteur [33]) for 4 consecutive weeks.
Immunofluorescence (IF) of mouse tissues
Urinary bladders were processed for IF according to
published methods [56] to determine the effects of BCG
and VEGF on the density of nerves. Briefly, mice were
exposed to isofluorane, and when anesthesia was
obtained, mice were euthanized by cervical dislocation,
bladders were removed, urine was drained, and tissues
were frozen immediately in 1:1 tissue freezing media
(TFM, Triangle Biomed Sciences) and OCT (Tissue
Tek
®). For all tissues, appropriate cross-section mor-
phology was confirmed by H&E staining and examina-
tion by light microscopy prior to preparing slides for IF
labeling. Frozen sections (10 μm thick) were post-fixed
in 1% MeOH-free formaldehyde for all staining except
for the CGRP antibody as subsequently described.
Briefly, slides were blocked for 35 minutes with 5% nor-
mal donkey serum (NDS; Jackson Immunolabs), then
co-incubated with primary antibodies in 0.5% NDS for
9 0m i n u t e si nah u m i d i f i e dc h a m b e ro ro v e r n i g h ta t4 °
C. When double IF was used, following brief rinses with
PBS, slides were co-incubated with both secondary anti-
bodies at the same time. All secondary antibodies were
used at a 1:400 dilution and included donkey anti-rabbit
IgG Alexafluor 488 and 546 conjugate (Molecular
Probes), donkey anti-goat IgG Alexafluor 546, donkey
anti-rat IgG Alexafluor 488, and goat anti-guinea pig
546. Slides were washed, counterstained with 4’,6 - d i a -
midino-2-phenylindole (DAPI), and coverslipped. Con-
trols included slides labeled only with individual primary
and secondary antibodies, as well as secondary antibo-
dies only. CGRP labeling was performed by fixing tissues
with 4% p-formaldehyde for 90 minutes at 4°C, then
blocking with 10% NDS/0.3% Triton/0.1% BSA for 1
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t h eC G R Pa n t i b o d yi nP B S / 0 . 3 %T r i t o n / 0 . 1 %B S Ao v e r -
night at 4°C in a humidified chamber. After brief washes
the slides were stained with the appropriate secondary
antibody and counterstained with DAPI and
coverslipped.
Primary antibodies
TRPV1 antibody (1:10, 000) was raised in rabbits against
the 15 C-terminal amino acids of the rat TRPV1
sequence [37]. Commercially available antibodies
included: rabbit anti-human protein gene product 9.5
[PGP9.5] (Neuromics; catalog # RB12103, 1:1500 dilu-
tion), rabbit anti-mouse substance P (Millipore; catalog
AB1566; 1:250 dilution), guinea pig anti-rat substance P
(Millipore; catalog AB15810; 1:1000 dilution), rabbit
anti-rat CGRP (Immunostar; catalog # 24112; 1:1000
dilution), rabbit anti-human myeloperoxidase (Dako;
catalog #A0398; 1:600 dilution), rat anti-mouse Pecam
(CD31; BD Pharmingen; catalog 550274; 1:50 dilution),
goat anti-mouse KI-67 (Santa Cruz; catalog # sc-7846;
1:75 dilution), and goat anti-mouse F4/80 (Santa Cruz;
catalog# sc-26642; 1:100 dilution).
Image analysis
Sections were viewed and photographed using a Zeiss
LSM-510META scanning confocal microscope (Thorn-
wood, NY) using a Zeiss axiocam HRm high-resolution
CCD camera, driven by Axiovision 4.6 software. For
image analysis, all tissue cross-sections were viewed
with a Nikon Eclipse TE 2000-S inverted fluorescent
microscope and imaged at room temperature using a
digital CCD camera (Roper Scientific; Sarasota, Florida
34240) driven by NIS-Elements AR 3.0 Imaging soft-
ware. DAPI staining was viewed using a DAPI filter set
(340-380 nm ex, 435-485 nm em). Imaging of Alexafluor
488 utilized an excitation filter of 465-495 nm and an
emission filter of 515-555 nm. Alexafluor 546 was
imaged with an excitation of 528-553 nm and 590-650
nm emission range. A control slide stained only with
secondary antibody was used to determine exposure
time and to set minimum background fluorescence
levels for each fluorophore imaged. Once set, exposure
times were not changed during acquisition of each
respective fluorophore in the staining series. Staining
was considered positive only when the acquired signal
exceeded the established background. Absence of signal
bleed-through was determined using previously opti-
mized multi-acquisition settings on single fluorophore
stained slides.
Inflammatory cells
For image analysis of MPO+ and F4/80+ positive
inflammatory cells, NIS-Elements AR 3.0 Imaging
software was set to include signals with an equivalent
diameter between 1-10.9 μm
2 [The equivalent diameter
is a size feature derived from the area. It determines the
diameter of a circle with the same area as the measured
object: Eqdia = sqrt (4*Area/p)] and to exclude any sig-
nal with an area smaller than 1 μm
2.
Nerve fibers
Histologically nerve fibers undulate in and out of the
plane of the section, sometimes appearing as linear
structures, and sometimes punctate staining, presumed
indicating nerves in cross-section. Therefore, the follow-
ing parameters were used in order to exclude structures
above or below a certain size as being potentially non-
neuronal and to exclude inflammatory cells since mono-
cytes and macrophages have been reported to express
T R P V 1[ 6 5 ] .I nt h i sc o n t e x t ,f o ri m a g ea n a l y s i so f
nerves, the NIS-Elements AR 3.0 Imaging software was
set to count only structures with length between 0.19-
500 μm and width 0.19-2.5 μm. [Length is a derived fea-
ture appropriate for elongated or thin structures. Length
= (Perimeter + sqrt (Perimeter
2 - 16*Area))/4]; and
Width is a derived feature appropriate for elongated or
thin structures. It is based on the rod model and is cal-
culated according to the following formula: Width =
Area/Length].
Blood vessels and Angiogenesis
Microvessel density (MVD) was determined by comput-
ing the area occupied by CD31+ blood vessels that was
expressed as percent of the cross-sectional area. Angio-
genesis was defined by the proliferation of CD31+ blood
vessels. For this purpose, the expression a marker of
proliferation (KI67) was calculated taking CD31+ blood
vessels as region of interest (ROI).
To meet the independent randomized sampling
assumption required for our statistical test(s), the fol-
lowing measures were taken: blinding the reader to
treatment groups and picking a random starting position
and proceeding clockwise with 6-10 non-overlapping
images. As 12-20 fields are necessary to view the whole
bladder cross-section at 400× magnification, the sam-
pling of 6-10 non-overlapping images represented half
o ft h ee n t i r eb l a d d e rc r o s s - section. The area occupied
by cells stained positively by a particular antibody was
calculated as percent of the total area of the region of
interest (ROI), as indicated in the individual figure
legend and the results of 6-10 fields were averaged. This
procedure was repeated for all 8 bladders used per treat-
ment group and the results are expressed as mean ±
SEM of 8 cross-sections. The data were examined to
determine if the distributions were homoscedastic and
Gaussian. As these conditions were met, groups were
compared through a two-sample Student’stt e s t .A n
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values were adjusted for multiple comparisons through
a Bonferroni correction.
This manuscript reports the results obtained with 13
experimental groups (PBS i.p. and 4 weekly instilla-
tions of BCG; PBS i.p. and 4 weekly instillations PBS;
single instillation of VEGF165, 4 weekly instillations of
VEGF165, 6 weekly instillations of VEGF165;s i n g l e
instillation of VEGF121; 4 weekly instillations of
VEGF121; avastin i.p. and 4 weekly instillations of BCG;
B20 i.p. and 4 weekly instillations of BCG; NRP1
A i.p.
4 weekly instillations of BCG; NRP1
B i.p. 4 weekly
instillations of BCG; NRP
2B i.p 4 weekly instillations of
BCG; and NRP2
B i.p. 4 weekly instillations of PBS),
containing 8 mice per group, for a total of 104 mice.
In addition to H&E, image analysis was performed in
least 6-10 non-overlapping images of all bladder cross-
sections stained with 8 different antibodies (CD31,
Ki67, PGP, TRPV1, CGRP, SP, MPO, and F4/80). The
rationale for performing in vitro image analysis of
nerves, blood vessels, and inflammatory cells using the
same cross-sections obtained from animals submitted
to 13 different treatments was to permit the proper
comparisons. In order to better organize the results
and to improve the manuscript readability the results
were separated in different sections. The latter does
not imply that experiments were performed in addition
to the ones described above.
Reagents
Mouse recombinant VEGF165 (catalog # MGC70609)
and VEGF121 (catalog # CYT-574) were purchased from
ProSpec-Tany TechnoGene Ltd (Rehovot 76124, Israel).
TheraCys
© BCG was purchased from Sanofi-Pasteur.
Anti-NRP1
A,a n t i - N R P 1
B, anti-NRP2
B, B20, and Avastin
were obtained from Genentech Corp.
Acknowledgements and funding
This entire research was supported by the Department of Defense Medical
Research Program (PRMRP) under award number PR080981 (RS). Views and
opinions of, and endorsements by the author(s) do not reflect those of the
US Army or the Department of Defense. Preliminary results were support in
part by award number 2-R56-DK66101 to RS. We thank Marissa K. Warma for
helping edit this manuscript.
Author details
1Department of Physiology, The University of Oklahoma Health Sciences
Center, Oklahoma City, OK 73104, USA.
2Department of Experimental
Biology, Faculty of Medicine of Porto and IBMC, 4200-319 Porto, Portugal.
3Department of Urology, Hospital São João, Faculty of Medicine of Porto
and IBMC, 4200-076 Porto, Portugal.
4Oklahoma Medical Research
Foundation (OMRF), Imaging Core Facility, Oklahoma City, Oklahoma 73104,
USA.
5Department of Surgical Sciences, School of Veterinary Medicine,
University of Wisconsin-Madison, Madison, WI 53706, USA.
6Departments of
Pediatrics and Biochemistry and Molecular Biology, University of Oklahoma
Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
7Departments
of Urology, Biochemistry, and Molecular Biology, University of Oklahoma
Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Authors’ contributions
All authors read and approved the final manuscript. MRS designed the
study, performed the in vivo experiments, and drafted the manuscript, CAD
performed IF imaging and analysis, AA participated in the experimental
design, provided TRPV1 tissues and antibody, FC participated in the
experimental design, JM performed tissue section, advised with IF
techniques, and helped CAD with confocal photomicrographs, DEB
participated in the experimental design and helped draft the manuscript,
TJS participate in the experimental design, interpretation of results, and draft
of the manuscript, REH participated in the experimental design, RS
conceived the study.
Competing interests
The authors declare that they have no competing interests.
Received: 23 June 2011 Accepted: 7 November 2011
Published: 7 November 2011
References
1. Avelino A, Cruz F: TRPV1 (vanilloid receptor) in the urinary tract:
expression, function and clinical applications. Naunyn Schmiedebergs Arch
Pharmacol 2006, 373(4):287-299.
2. Andersson KE, Hedlund P: Pharmacologic perspective on the physiology
of the lower urinary tract. Urology 2002, 60(5 Suppl 1):13-20, discussion
20-11.
3. Ford AP, Cockayne DA: ATP and P2X purinoceptors in urinary tract
disorders. Handb Exp Pharmacol 2011, , 202: 485-526.
4. Saban R, Saban MR, Nguyen NB, Lu B, Gerard C, Gerard NP, Hammond TG:
Neurokinin-1 (NK-1) receptor is required in antigen-induced cystitis. Am
J Pathol 2000, 156(3):775-780.
5. Saban R, D’Andrea MR, Andrade-Gordon P, Derian CK, Dozmorov I,
Ihnat MA, Hurst RE, Davis CA, Simpson C, Saban MR: Mandatory role of
proteinase-activated receptor 1 in experimental bladder inflammation.
BMC Physiol 2007, 7:4.
6. Schnegelsberg B, Sun TT, Cain G, Bhattacharya A, Nunn PA, Ford AP,
Vizzard MA, Cockayne DA: Overexpression of NGF in mouse urothelium
leads to neuronal hyperinnervation, pelvic sensitivity, and changes in
urinary bladder function. Am J Physiol Regul Integr Comp Physiol 2010,
298(3):R534-547.
7. Martin P, Lewis J: Origins of the neurovascular bundle: interactions
between developing nerves and blood vessels in embryonic chick skin.
Int J Dev Biol 1989, 33(3):379-387.
8. Mukouyama YS, Shin D, Britsch S, Taniguchi M, Anderson DJ: Sensory
nerves determine the pattern of arterial differentiation and blood vessel
branching in the skin. Cell 2002, 109(6):693-705.
9. Pereira Lopes FR, Lisboa BC, Frattini F, Almeida FM, Tomaz MA,
Matsumoto PK, Langone F, Lora S, Melo PA, Borojevic R, Han SW,
Martinez AM: Enhancement of sciatic-nerve regeneration after VEGF
gene therapy. Neuropathol Appl Neurobiol 2011.
10. Carmeliet P, Tessier-Lavigne M: Common mechanisms of nerve and blood
vessel wiring. Nature 2005, 436(7048):193-200.
11. Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K,
Eichmann A: Abnormal lymphatic vessel development in neuropilin 2
mutant mice. Development 2002, 129(20):4797-4806.
12. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P: Role and
therapeutic potential of VEGF in the nervous system. Physiol Rev 2009,
89(2):607-648.
13. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M: Neuropilins in
neoplasms: expression, regulation, and function. Exp Cell Res 2006,
312(5):584-593.
14. Suzuki K, Kumanogoh A, Kikutani H: Semaphorins and their receptors in
immune cell interactions. Nat Immunol 2008, 9(1):17-23.
15. Adams RH, Eichmann A: Axon guidance molecules in vascular patterning.
Cold Spring Harb Perspect Biol 2010, 2(5):a001875.
16. Wen H, Lei Y, Eun SY, Ting JP: Plexin-A4-semaphorin 3A signaling is
required for Toll-like receptor- and sepsis-induced cytokine storm. J Exp
Med 2010, 207(13):2943-2957.
17. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M: Neuropilin-2, a
novel member of the neuropilin family, is a high affinity receptor for the
semaphorins Sema E and Sema IV but not Sema III. Neuron 1997,
19(3):547-559.
Saban et al. BMC Physiology 2011, 11:16
http://www.biomedcentral.com/1472-6793/11/16
Page 18 of 2018. Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, Kolodkin AL:
Neuropilin-2 is a receptor for semaphorin IV: insight into the structural
basis of receptor function and specificity. Neuron 1998, 21(5):1079-1092.
19. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M: Neuropilin-1 is
expressed by endothelial and tumor cells as an isoform-specific receptor
for vascular endothelial growth factor. Cell 1998, 92(6):735-745.
20. Takamatsu H, Takegahara N, Nakagawa Y, Tomura M, Taniguchi M,
Friedel RH, Rayburn H, Tessier-Lavigne M, Yoshida Y, Okuno T, Mizui M,
Kang S, Nojima S, Tsujimura T, Nakatsuji Y, Katayama I, Toyofuku T,
Kikutani H, Kumanogoh A: Semaphorins guide the entry of dendritic cells
into the lymphatics by activating myosin II. Nat Immunol 2010,
11(7):594-600.
21. Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivee B, Del
Toro R, Suchting S, Medvinsky A, Silva J, Yang J, Thomas JL, Koch AW,
Alitalo K, Eichmann A, Bagri A: Neuropilin-2 mediates VEGF-C-induced
lymphatic sprouting together with VEGFR3. J Cell Biol 2010,
188(1):115-130.
22. Saban R, Saban MR, Maier J, Fowler B, Tengowski M, Davis CA, Wu XR,
Culkin DJ, Hauser P, Backer J, Hurst RE: Urothelial expression of
neuropilins and VEGF receptors in control and interstitial cystitis
patients. Am J Physiol Renal Physiol 2008, 295(6):F1613-1623.
23. Saban MR, Backer JM, Backer MV, Maier J, Fowler B, Davis CA, Simpson C,
Wu XR, Birder L, Freeman MR, Soker S, Hurst RE, Saban R: VEGF receptors
and neuropilins are expressed in the urothelial and neuronal cells in
normal mouse urinary bladder and are upregulated in inflammation. Am
J Physiol Renal Physiol 2008, 295(1):F60-72.
24. Bannerman P, Ara J, Hahn A, Hong L, McCauley E, Friesen K, Pleasure D:
Peripheral nerve regeneration is delayed in neuropilin 2-deficient mice. J
Neurosci Res 2008, 86(14):3163-3169.
25. Yazdani U, Terman JR: The semaphorins. Genome Biol 2006, 7(3):211.
26. Tanelian DL, Barry MA, Johnston SA, Le T, Smith GM: Semaphorin III can
repulse and inhibit adult sensory afferents in vivo. Nat Med 1997,
3(12):1398-1401.
27. Hayashi M, Kamiya Y, Itoh H, Higashi T, Miyazaki T, Funakoshi K,
Yamashita N, Goshima Y, Andoh T, Yamada Y, Goto T: Intrathecally
administered Sema3A protein attenuates neuropathic pain behavior in
rats with chronic constriction injury of the sciatic nerve. Neurosci Res
2011, 69(1):17-24.
28. Messersmith EK, Leonardo ED, Shatz CJ, Tessier-Lavigne M, Goodman CS,
Kolodkin AL: Semaphorin III can function as a selective chemorepellent
to pattern sensory projections in the spinal cord. Neuron 1995,
14(5):949-959.
29. Ji JD, Park-Min KH, Ivashkiv LB: Expression and function of semaphorin 3A
and its receptors in human monocyte-derived macrophages. Hum
Immunol 2009, 70(4):211-217.
30. Carmeliet P: Blood vessels and nerves: common signals, pathways and
diseases. Nat Rev Genet 2003, 4(9):710-720.
31. Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, Mandron M,
Herault JP, Neufeld G, Savi P, Herbert JM, Bono F: Neuropilin-2 interacts
with VEGFR-2 and VEGFR-3 and promotes human endothelial cell
survival and migration. Blood 2006, 108(4):1243-1250.
32. Pavlovich CP, Kraling BM, Stewart RJ, Chen X, Bochner BH, Luster AD,
Poppas DP, O’Donnell MA: BCG-induced urinary cytokines inhibit
microvascular endothelial cell proliferation. J Urol 2000, 163(6):2014-2021.
33. Saban MR, Simpson C, Davis C, Wallis G, Knowlton N, Frank MB, Centola M,
Gallucci RM, Saban R: Discriminators of mouse bladder response to
intravesical Bacillus Calmette-Guerin (BCG). BMC immunology 2007, 8:6.
34. Li Z, Burns AR, Han L, Rumbaut RE, Smith CW: IL-17 and VEGF are
necessary for efficient corneal nerve regeneration. Am J Pathol 2011,
178(3):1106-1116.
35. Charrua A, Reguenga C, Cordeiro JM, Correiade-Sa P, Paule C, Nagy I,
Cruz F, Avelino A: Functional transient receptor potential vanilloid 1 is
expressed in human urothelial cells. J Urol 2009, 182(6):2944-2950.
36. Doran JF, Jackson P, Kynoch PA, Thompson RJ: Isolation of PGP 9.5, a new
human neurone-specific protein detected by high-resolution two-
dimensional electrophoresis. J Neurochem 1983, 40(6):1542-1547.
37. Charrua A, Cruz CD, Narayanan S, Gharat L, Gullapalli S, Cruz F, Avelino A:
GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder
overactivity and noxious bladder input in cystitis animal models. J Urol
2009, 181(1):379-386.
38. Carmeliet P: Neuro-vascular link: from genetic insights to therapeutic
perspectives. Bull Mem Acad R Med Belg 2008, 163(10-12):445-451,
discussion 451-442.
39. Mac Gabhann F, Popel AS: Targeting neuropilin-1 to inhibit VEGF
signaling in cancer: Comparison of therapeutic approaches. PLoS Comput
Biol 2006, 2(12):e180.
40. Mac Gabhann F, Popel AS: Interactions of VEGF isoforms with VEGFR-1,
VEGFR-2, and neuropilin in vivo: a computational model of human
skeletal muscle. Am J Physiol Heart Circ Physiol 2007, 292(1):H459-474.
41. Kuruvilla R, Zweifel LS, Glebova NO, Lonze BE, Valdez G, Ye H, Ginty DD: A
neurotrophin signaling cascade coordinates sympathetic neuron
development through differential control of TrkA trafficking and
retrograde signaling. Cell 2004, 118(2):243-255.
42. Tamaki M, Saito R, Ogawa O, Yoshimura N, Ueda T: Possible mechanisms
inducing glomerulations in interstitial cystitis: relationship between
endoscopic findings and expression of angiogenic growth factors. J Urol
2004, 172(3):945-948.
43. Kim CF, Moalem-Taylor G: Interleukin-17 contributes to
neuroinflammation and neuropathic pain following peripheral nerve
injury in mice. J Pain 2011, 12(3):370-383.
44. Perkins NM, Tracey DJ: Hyperalgesia due to nerve injury: role of
neutrophils. Neuroscience 2000, 101(3):745-757.
45. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG: Neuropilin-1 expression
on regulatory T cells enhances their interactions with dendritic cells
during antigen recognition. Immunity 2008, 28(3):402-413.
46. Mizui M, Kikutani H: Neuropilin-1: the glue between regulatory T cells
and dendritic cells? Immunity 2008, 28(3):302-303.
47. Bruder D, Probst-Kepper M, Westendorf AM, Geffers R, Beissert S, Loser K,
von Boehmer H, Buer J, Hansen W: Neuropilin-1: a surface marker of
regulatory T cells. Eur J Immunol 2004, 34(3):623-630.
48. Battaglia A, Buzzonetti A, Monego G, Peri L, Ferrandina G, Fanfani F,
Scambia G, Fattorossi A: Neuropilin-1 expression identifies a subset of
regulatory T cells in human lymph nodes that is modulated by
preoperative chemoradiation therapy in cervical cancer. Immunology
2008, 123(1):129-138.
49. Muller MW, Giese NA, Swiercz JM, Ceyhan GO, Esposito I, Hinz U, Buchler P,
Giese T, Buchler MW, Offermanns S, Friess H: Association of axon guidance
factor semaphorin 3A with poor outcome in pancreatic cancer. Int J
Cancer 2007, 121(11):2421-2433.
50. Long JB, Jay SM, Segal SS, Madri JA: VEGF-A and Semaphorin3A:
modulators of vascular sympathetic innervation. Dev Biol 2009,
334(1):119-132.
51. Brockington A, Wharton SB, Fernando M, Gelsthorpe CH, Baxter L, Ince PG,
Lewis CE, Shaw PJ: Expression of vascular endothelial growth factor and
its receptors in the central nervous system in amyotrophic lateral
sclerosis. J Neuropathol Exp Neurol 2006, 65(1):26-36.
52. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, Stewart WB,
Madri JA, Ment LR: Paracrine and autocrine functions of neuronal
vascular endothelial growth factor (VEGF) in the central nervous system.
J Biol Chem 2002, 277(13):11410-11415.
53. Damon DH: Vascular endothelial-derived semaphorin 3 inhibits
sympathetic axon growth. Am J Physiol Heart Circ Physiol 2006, 290(3):
H1220-1225.
54. Marko SB, Damon DH: VEGF promotes vascular sympathetic innervation.
Am J Physiol Heart Circ Physiol 2008, 294(6):H2646-2652.
55. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K,
Peoples GE, Klagsbrun M: Peripheral blood T lymphocytes and
lymphocytes infiltrating human cancers express vascular endothelial
growth factor: a potential role for T cells in angiogenesis. Cancer Res
1995, 55(18):4140-4145.
56. Saban MR, Sferra TJ, Davis CA, Simpson C, Allen A, Maier J, Fowler B,
Knowlton N, Birder L, Wu XR, Saban R: Neuropilin-VEGF signaling pathway
acts as a key modulator of vascular, lymphatic, and inflammatory cell
responses of the bladder to intravesical BCG treatment. Am J Physiol
Renal Physiol 2010, 299(6):F1245-1256.
57. Appleton BA, Wu P, Maloney J, Yin J, Liang WC, Stawicki S, Mortara K,
Bowman KK, Elliott JM, Desmarais W, Bazan JF, Bagri A, Tessier-Lavigne M,
Koch AW, Wu Y, Watts RJ, Wiesmann C: Structural studies of neuropilin/
antibody complexes provide insights into semaphorin and VEGF
binding. Embo J 2007, 26(23):4902-4912.
Saban et al. BMC Physiology 2011, 11:16
http://www.biomedcentral.com/1472-6793/11/16
Page 19 of 2058. Chen H, He Z, Bagri A, Tessier-Lavigne M: Semaphorin-neuropilin
interactions underlying sympathetic axon responses to class III
semaphorins. Neuron 1998, 21(6):1283-1290.
59. Hillen F, van de Winkel A, Creytens D, Vermeulen AH, Griffioen AW:
Proliferating endothelial cells, but not microvessel density, are a
prognostic parameter in human cutaneous melanoma. Melanoma Res
2006, 16(5):453-457.
60. Silva C, Avelino A, Souto-Moura C, Cruz F: A light- and electron-
microscopic histopathological study of human bladder mucosa after
intravesical resiniferatoxin application. BJU Int 2001, 88(4):355-360.
61. Geuna S, Fornaro M, Raimondo S, Giacobini-Robecchi MG: Plasticity and
regeneration in the peripheral nervous system. Ital J Anat Embryol 2010,
115(1-2):91-94.
62. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y, Eigenbrot C,
Yin J, Koch AW, Wu X, Ferrara N, Bagri A, Tessier-Lavigne M, Watts RJ, Wu Y:
Function blocking antibodies to neuropilin-1 generated from a designed
human synthetic antibody phage library. J Mol Biol 2007, 366(3):815-829.
63. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C: Structure-
function studies of two synthetic anti-vascular endothelial growth factor
Fabs and comparison with the Avastin Fab. J Biol Chem 2006,
281(10):6625-6631.
64. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK,
Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G,
Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ: Blocking
neuropilin-1 function has an additive effect with anti-VEGF to inhibit
tumor growth. Cancer Cell 2007, 11(1):53-67.
65. Finney-Hayward TK, Popa MO, Bahra P, Li S, Poll CT, Gosling M,
Nicholson AG, Russell RE, Kon OM, Jarai G, Westwick J, Barnes PJ,
Donnelly LE: Expression of transient receptor potential c6 channels in
human lung macrophages. American journal of respiratory cell and
molecular biology 2010, 43(3):296-304.
doi:10.1186/1472-6793-11-16
Cite this article as: Saban et al.: VEGF signaling mediates bladder
neuroplasticity and inflammation in response to BCG. BMC Physiology
2011 11:16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Saban et al. BMC Physiology 2011, 11:16
http://www.biomedcentral.com/1472-6793/11/16
Page 20 of 20